Nektar Therapeutics NKTR Accrued liabilities
Accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccruedLiabilities.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Nektar Therapeutics's accrued liabilities?
- Nektar Therapeutics (NKTR) reported accrued liabilities of $2.33M in Q1 2026.
- How has Nektar Therapeutics's accrued liabilities changed year-over-year?
- Nektar Therapeutics's accrued liabilities increased by 91.4% year-over-year, from $1.22M to $2.33M.